Press Releases

Dr. Uri Geiger

Chairman of the Board

Uri Geiger brings extensive entrepreneurial, management and investment know-how, having created and built many successful medical device enterprises.

Prior to founding Accelmed, Dr. Geiger founded served as CEO of Exalenz Bioscience Ltd. (TASE:EXEN), developer of an innovative breath-based technology for diagnosing liver and gastrointestinal disorders which Dr. Geiger took public in 2007 and later sold to Meridian (NASDAQ: VIVO). Prior to Exalenz, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components, sold in 2003 to MEMSCAP (EuroNext: MEMS). Dr. Geiger is also the founding partner of Dragon Variation Fund, one of Israel’s first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of capital markets and significant experience, which he put to use after returning to Israel in 1999.

Dr. Geiger was formerly an adjunct professor at the Recanati Business School at Tel Aviv University, where he lectured on private equity and venture capital. He is the author of the books: Startup Companies and Venture Capital (Tel Aviv University Press, 2001) and From Concept to Wall Street (Financial Times – Prentice Hall, 2003). He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as a major in the Israeli Air Force.

Lior Shav

Board Member

Lior Shav is a General Partner at Accelmed where he focuses primarily on buyout transactions. Mr. Shav has over 20 years of experience in business development, investment banking and consulting, primarily in the healthcare space including M&A deals, private placements, private equity transactions, PIPEs and other financial transactions. Prior to joining Accelmed, Lior served in a number of business Development roles and established and managed Shav Consulting, an Israeli healthcare business consulting firm. Prior to that, Lior managed the corporate finance activity of Meitav Capital Markets and served as an analyst in Meitav Corporate Finance Consultant, both subsidiaries of Meitav, one of Israel largest investment management groups. Lior was a co-founder of ETView Ltd. (TASE listed, MedTech company sold in 2016 to Ambu) as well as two other startups. Mr. Shav earned a B.Sc. in Industrial Engineering & Management from the Technion-Israel Institute of Technology in 2001 and a M.A. in Political Science from Tel Aviv University in 2005.

Erin Enright

Board Member

Erin S. Enright currently serves as a Managing Member of Prettybrook Partners LLC, a family office dedicated to investing in healthcare companies. Prettybrook has approximately 20 active investments in a variety of companies, typically as a co-investor with institutional private equity. She serves as the Chairman of the Board, Chair of the Nominating and Governance Committee and member of the Audit Committee and Compensation Committee of Dynatronics Corporation (NASDAQ: DYNT), and as a member of the Board of Directors, Chairman of the Investment Committee and member of the Audit Committee of Medical Facilities Corporation (TSX: DR) and a member of the Board and Chair of the Audit Committee of Keystone Dental, Inc., a private company controlled by the private equity firm Accelmed. Previously, she served on the Board of Directors and the Audit Committee of Biolase, Inc. (NASDAQ: BIOL) during 2013, was a member of the Board of Directors of Tigerlabs, a Princeton-based business accelerator, from 2012 to 2018, and from 2010 to 2015 served on the Board of Directors of Ceelite Technologies, LLC. She was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004-13. She was Chief Financial Officer of InfuSystem, Inc. (NASDAQ:INFU) from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, most recently as a Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and J.D. from the University of Chicago Law School.

Howard Zauberman

Board Member

Howard has over 40 years of experience as a leader in the medical products industry. He was previously CEO of Vision Sciences, an endoscope manufacturer, and a member of the Board of Directors of Cogentix Medical, a urology products company. Prior to that, Howard was Vice President of Business Development at Henry Schein, a leading global healthcare distributor serving office based dental and medical practitioners. Howard also served as a Special Venture Partner at Galen Partners, a healthcare growth equity firm. Prior to this Howard held senior management positions at ETHICON, a Johnson & Johnson company, and Pfizer. Howard has a Masters of Engineering Management from Northwestern University, a Bachelor of Science from Columbia University in mechanical engineering and a Bachelor’s degree from Queens College.

Michael Tuckman

Board Member

Michael Tuckman is a dental technician and mechanical engineer, specializing in advanced CAD/CAM technology. The founder and CEO of Osteon Medical, Michael has a passion for combining engineering with dental implantology to develop and commercialize new and innovative implant products. He enjoys working collaboratively with many of Australia’s respected universities and research institutions to deliver the latest generation developments in advanced CAD/CAM technology and his work has been featured in both local and international publications.